Literature DB >> 3877236

Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation.

N L Rosenberg, J R Lacy, R C Kennaugh, V M Holers, H E Neville, B L Kotzin.   

Abstract

Four patients with refractory or poorly responsive chronic progressive demyelinating polyneuropathy (CPDP) were treated with total lymphoid irradiation (total dose, 2000 rad) in an uncontrolled feasibility study. All patients had previously failed conventional therapy for CPDP, as well as other unconventional treatments. During a follow-up period of 7 to 12 months after total lymphoid irradiation, there was a profound and sustained suppression of the absolute lymphocyte count and in vitro lymphocyte function, as well as an increase in the ratio of Leu-2 (suppressor/cytotoxic subset) to Leu-3 (helper/inducer subset) T cells in the blood. Three of the four patients demonstrated improvement in distal muscle strength, and this was associated with increased functional capabilities in two patients. In contrast, no clinical improvement in sensation was noted in any patient. Nerve conduction studies showed patchy improvement in three patients. The results of this preliminary uncontrolled study indicate that radiotherapy deserves further study in the treatment of CPDP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3877236     DOI: 10.1002/mus.880080308

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Chronic Inflammatory Demyelinating Polyneuropathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.598

2.  An update on the management of chronic inflammatory demyelinating polyneuropathy.

Authors:  Kenneth C Gorson
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

3.  Treatment of peripheral neuropathies.

Authors:  M Hallett; D Tandon; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-12       Impact factor: 10.154

4.  Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy.

Authors:  S J Hodgkinson; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-04       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.